The Danish nicotine chewing gum manufacturer Fertin Pharma, whose majority shareholder is the private equity fund EQT, has acquired two companies located in Denmark and Canada.
The company located in Denmark, Medcan Pharma, develops cannabis for medicinal use. The global market for pharmaceutical and medicinal use of cannabis is a growing market. The intention is that Fertin Pharma’s knowledge of oral administration of active pharmaceutical ingredients, e.g. in the form of chewing gum, combined with Medcan Pharma’s knowledge of the use of cannabinoids will prepare the companies for taking part in such growth.
Fertin Pharma has also acquired the Canadian company Tab Labs Inc. that manufactures chewing gum, mints and lozenges at its headquarters in Vancouver, Canada. The acquisition will serve as Fertin Pharma’s way into the North American market where legalisation of cannabinoid-containing products is spreading, and which is estimated to reach a value of more than USD 1bn in 2023.
Accura advised Fertin Pharma in both transactions.